Bausch Health Companies Inc.

NYQ: BHC

Live Quote

📈 ZcoreAI Score

Our AI model analyzes Bausch Health Companies Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get BHC Z-Score →

About Bausch Health Companies Inc.

Healthcare Drug Manufacturers - Specialty & Generic

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

📊 Fundamental Analysis

Bausch Health Companies Inc. demonstrates a profit margin of 1.5%, which is below the sector average, suggesting competitive pressure.

The company recently reported 9.3% revenue growth, which is above average for the Healthcare sector.

Return on Equity (ROE) is 436.4%, which reflects exceptional capital efficiency.

At a current price of $5.60, BHC currently sits at the 30th percentile of its 52-week range (Range: $4.28 - $8.69).

💰 Valuation Insight

BHC trades at a 46.7% discount (PE: 13.33), which may represent a value opportunity given the sector average of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.

🏥 Financial Health

🔴 Profit Margin Weak

🔴 Debt/Equity Elevated

⚠️ Revenue Growth Moderate

✅ Return on Equity Excellent

✅ Beta (Risk) Low Volatility

Key Financials

Market Cap

$2.09B

Trailing P/E

13.33

Forward P/E

1.39

Beta (5Y)

0.40

52W High

$8.69

52W Low

$4.28

Avg Volume

2.12M

Day High

Day Low

Get BHC Z-Score on Dashboard 🚀